PARIS—Brace yourself for a new wave of hydroxychloroquine hype. The eccentric French researcher whose findings have captured the imagination of Donald Trump and the airtime of enthusiastic Fox News pundits has just published new findings clearly intended to answer his critics. On Thursday evening, when French President Emmanuel Macron made a previously unannounced visit to Dr. Didier Raoult’s research institute in Marseilles, the doctor reported that his staff had treated 1,061 patients with confirmed cases of COVID-19 employing hydroxychloroquine (HCQ), a common anti-malarial drug, and the antibiotic azithromycin (AZ). The the two-page paper Raoul made public: “98 percent of patients cured so far.” After 10 days of treatment, Raoult claims, 91.7 percent were rid of the virus, while a mere 4.3 percent had “a poor outcome,” with 10 patients moved to the ICU, and five dead. If these results are accurate and the treatment with readily available drugs is as good as all that, then it more than 100,000 deaths around the globe as of this writing. If only the world had listened to Dr. Raoult when he promoted his first conclusions earlier this year based on a sampling of 24 patients. But there are quite a few reasons Raoult’s… Read full this story
- Guide to Healthy Relationships - Will a Miracle Drug Erase Bad Memories So You Remember the Love?
- Harry Dunn's parents meet President Trump at White House
- Harry Dunn's parents turn down meeting with Anne Sacoolas as Trump intervenes to broker solution
- Republican senators both blast and praise Trump's Syria policy
- The Dark Side of Prescription Drugs
- Online Artist Networking
- Do Penis Enlargement Drugs Have Any Side Effects?
- Alcohol & Drug Treatment Programs
- Drug Addicted Daughter - A Mother Finds Help and Hope
- Help With Drug Addiction at Anonymous Meetings - My Experience
Meet the B.S. Artist Behind Trump’s Miracle Drug have 305 words, post on www.thedailybeast.com at April 10, 2020. This is cached page on USA Breaking News. If you want remove this page, please contact us.